Why Clay Siegall’s Appointment to Mirna Therapeutics’ Board is a Major Corporate Coup

When Mirna Therapeutic appointed Dr. Clay Siegall to its board of directors recently, many observers interpreted this as a strategic move. This is because Dr. Siegall has had a long and illustrious career in the biotechnology industry. His experience will help Mirna Therapeutics to advance its operations to new markets. He will serve the firm’s board in the capacity of an outside director.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Mirna Therapeutics is a pharmaceutical company based in Austin, Texas. It was formed in 2007 and mainly focuses on the advancement of microRNA therapies, which are used in cancer treatment. Dr. Siegall is widely experienced in this field. While announcing the appointment, Mirna Therapeutics’ president and CEO, Dr. Paul Lammers expressed his excitement with the prospect of working with a trusted and renowned industry leader. He further stated that Mirna is delighted to have Siegall on its board.

Dr. Siegall in Brief

Clay Siegall is a prominent biotechnologist who is mainly involved in cancer research. He is synonymous with the formation of Seattle Genetics. He serves as the firm’s president and CEO The firm was founded in 1998 with the purpose of advancing world-class cancer therapies. It similarly focuses on the development and commercialization of innovative and legal anti-body based cancer therapies.

The direction given by Siegall and the board has seen the firm’s products gaining global prominence. Its first commercially available product ADCETRIS, is used in over 70 countries. Dr. Siegall is a graduate of the University of Maryland, and the George Washington University. He had a successful career in the field of medical research, which culminated in him publishing more than 70 research papers and books.

Before Seattle Genetics was formed, Siegall was a distinguished employee at the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institute of Health, and the National Cancer Institute where he developed an interest in the field of cancer research. As Seattle Genetics’ CEO, he has pioneered the adoption of MMNAE and PB- based technologies. This has gone a long way in helping the firm to advance high quality products. He is credited with sourcing for funds that facilitated the construction of a million-dollar research facility in Washington where Seattle Genetics is based.

Learn more: